Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberWO2005000235 A3
Publication typeApplication
Application numberPCT/US2004/018962
Publication date16 Jun 2005
Filing date14 Jun 2004
Priority date13 Jun 2003
Also published asCA2529145A1, CA2529145C, CN1832956A, CN1832956B, EP1638987A2, EP1638987A4, EP1638987B1, EP2292634A2, EP2292634A3, US8173786, US20070041941, US20120276142, WO2005000235A2
Publication numberPCT/2004/18962, PCT/US/2004/018962, PCT/US/2004/18962, PCT/US/4/018962, PCT/US/4/18962, PCT/US2004/018962, PCT/US2004/18962, PCT/US2004018962, PCT/US200418962, PCT/US4/018962, PCT/US4/18962, PCT/US4018962, PCT/US418962, WO 2005/000235 A3, WO 2005000235 A3, WO 2005000235A3, WO-A3-2005000235, WO2005/000235A3, WO2005000235 A3, WO2005000235A3
InventorsDavid B Weiner, Michele Kutzler, Andrew K Choo, Joo-Sung Yang, Jean D Boyer
ApplicantUniv Pennsylvania, David B Weiner, Michele Kutzler, Andrew K Choo, Joo-Sung Yang, Jean D Boyer
Export CitationBiBTeX, EndNote, RefMan
External Links: Patentscope, Espacenet
NUCLEIC ACID SEQUENCES ENCODING AND COMPOSITIONS COMPRISING IgE SIGNAL PEPTIDE AND/OR IL-15 AND METHODS FOR USING THE SAME
WO 2005000235 A3
Abstract
Fusion proteins and nucleic acid molecules encoding fusion proteins are disclosed. Fusion proteins comprising non-IL-15 signal peptide linked to IL-15 protein sequences and fusion proteins comprising an IgE signal peptide linked to non-IgE protein sequences are disclosed. Vectors comprising such nucleic acid molecules; and to host cells comprising such vectors are disclosed as well as recombinant vaccines and live attenuated pathogens encoding fusion proteins, and methods of using the same, are disclosed. The immunomodulatory effect following delivery of IL-15 and CD40L, with or without immunogens, is disclosed as are various nucleic acid molecules and compositions thereof used for delivering such proteins and methods of using such compositions.
Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US20020123099 *4 Oct 20015 Sep 2002Weiner David B.Highly expressible genes
Non-Patent Citations
Reference
1 *ANETHER ET AL: 'Interleukin-15 as a potential costimulatory cytokine in CD154 gene therapy of chronic lymphocytic leukemia' BLOOD vol. 99, pages 722 - 723, XP002987799
2 *RUCKERT ET AL: 'II-15-IgG2b fusion protein accelerates and enhances a TH2 but not a Th1 immune response in vivo, while IL-2-IgG2b fusion protein inhibits both' EUR. J. IMMUNOL. vol. 28, December 1998, pages 3312 - 3320, XP002230807
3 *See also references of EP1638987A2
4 *WIERDA ET AL: 'CD40-ligand (CD145) gene therapy for chronic lymphocytic leukemia' BLOOD vol. 96, November 2000, pages 2917 - 2924, XP002987798
Classifications
International ClassificationC07K14/00, C07K14/52, A61P35/00, C07H21/04, A61K48/00, A61K, A61P37/00, C07K14/705, C07K14/54
Cooperative ClassificationA61K2039/53, A61K2039/55527, C07K2319/02, C07K14/70578, C07K14/5443
European ClassificationC07K14/54Q, C07K14/705R
Legal Events
DateCodeEventDescription
6 Jan 2005AKDesignated states
Kind code of ref document: A2
Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
6 Jan 2005ALDesignated countries for regional patents
Kind code of ref document: A2
Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
9 Mar 2005121Ep: the epo has been informed by wipo that ep was designated in this application
11 Dec 2005WWEWipo information: entry into national phase
Ref document number: 172496
Country of ref document: IL
12 Dec 2005WWEWipo information: entry into national phase
Ref document number: 544077
Country of ref document: NZ
Ref document number: 2529145
Country of ref document: CA
13 Dec 2005WWEWipo information: entry into national phase
Ref document number: PA/a/2005/013526
Country of ref document: MX
Ref document number: 1020057023994
Country of ref document: KR
Ref document number: 12005502247
Country of ref document: PH
Ref document number: 2006533791
Country of ref document: JP
15 Dec 2005WWEWipo information: entry into national phase
Ref document number: 2004251070
Country of ref document: AU
12 Jan 2006WWPWipo information: published in national office
Ref document number: 2004251070
Country of ref document: AU
12 Jan 2006WWEWipo information: entry into national phase
Ref document number: 2004776577
Country of ref document: EP
Ref document number: 200600336
Country of ref document: ZA
12 Jan 2006ENPEntry into the national phase in:
Ref document number: 2004251070
Country of ref document: AU
Date of ref document: 20040614
Kind code of ref document: A
29 Mar 2006WWPWipo information: published in national office
Ref document number: 2004776577
Country of ref document: EP
7 Apr 2006WWPWipo information: published in national office
Ref document number: 1020057023994
Country of ref document: KR
9 May 2006WWEWipo information: entry into national phase
Ref document number: 10560650
Country of ref document: US
Ref document number: 2007041941
Country of ref document: US
9 May 2006ENPEntry into the national phase in:
Ref document number: 2007041941
Country of ref document: US
Kind code of ref document: A1
25 Jul 2006ENPEntry into the national phase in:
Ref document number: PI0411363
Country of ref document: BR
22 Feb 2007WWPWipo information: published in national office
Ref document number: 10560650
Country of ref document: US